In this piece, we will take a look at Japanese billionaire Masayoshi Son’s investments: Top 5 stock picks. If you want to take a detailed look at Mr. Son’s top 10 companies and his investment firm, then head on to Japanese Billionaire Masayoshi Son’s Investments: Top 10 Stock Picks.
5. Sana Biotechnology, Inc. (NASDAQ:SANA)
SB Management’s holdings: $49.7 million
Percentage of SB Management’s Portfolio: 5.09%
Number of Hedge Fund Holders: 7
Sana Biotechnology, Inc. (NASDAQ:SANA) is an American cell engineering firm. Its cells, which refer to those present in the human body, target diseases such as diabetes, heart diseases, and nervous system disorders.
Mr. Son’s SB Management held 2.2 million Sana Biotechnology, Inc. (NASDAQ:SANA) shares as of the third quarter of 2021. These are worth $49.7 million and represent 5.09% of the firm’s portfolio. Out of the 867 hedge funds surveyed by Insider Monkey at Q3 2021 end, 7 held a stake in the company.
Sana Biotechnology, Inc. (NASDAQ:SANA) reported -$0.46 in GAAP EPS for its third quarter. In a March 2021 analyst note, Morgan Stanley set a $40 price target for the company, touting its disruptive abilities to replace dead cells in patients.
Sana Biotechnology, Inc. (NASDAQ:SANA)’s largest shareholder after SB Management is Jane Mendillo’s Harvard Management Co who holds 1.1 million shares worth $26 million.
4. Lyell Immunopharma, Inc. (NASDAQ:LYEL)
SB Management’s holdings: $51.8 million
Percentage of SB Management’s Portfolio: 5.3%
Number of Hedge Fund Holders: 10
Lyell Immunopharma, Inc. (NASDAQ:LYEL) is an American company that specializes in developing cancer treatments through t-cells. It was incorporated in 2018 and is headquartered in San Francisco, California.
Lyell Immunopharma, Inc. (NASDAQ:LYEL) reported $2.7 million in revenue and a net loss of $48.8 million in its third-quarter as it beat analyst estimates for revenue. In a July 2021 analyst note, JP Morgan set a $22 price target for the company, highlighting that Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s therapies have broad applications and can remove barriers for t-cell therapies.
By Q3 2021 end, Mr. Son’s SB Management held 3.5 million Lyell Immunopharma, Inc. (NASDAQ:LYEL) shares, in a stake worth $51.8 million and representing 5.3% of the firm’s portfolio. 10 of the 867 hedge funds surveyed by Insider Monkey during the same period had invested in the medical firm.
After SB Management, Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s a largest shareholder is Lei Zhang’s Hillhouse Capital Management who holds 2.3 million shares worth $34 million.
3. Sema4 Holdings Corp. (NASDAQ:SMFR)
SB Management’s holdings: $68 million
Percentage of SB Management’s Portfolio: 7.01%
Number of Hedge Fund Holders: 34
Sema4 Holdings Corp. (NASDAQ:SMFR) is a data driven diagnostics firm that uses artificial intelligence for drug discovery and commercialization. Additionally, it also provides cancer screening, diagnostics, and treatment. It is headquartered in Stamford, Connecticut.
Mr. Son’s SB Management held 9 million Sema4 Holdings Corp. (NASDAQ:SMFR) shares as Q3 2021 ended. These were worth $68 million and represented 7.01% of the firm’s portfolio. Out of the 867 hedge funds surveyed by Insider Monkey during the same time period, 34 held a stake in the company.
Sema4 Holdings Corp. (NASDAQ:SMFR) reported $43 million in revenue and $0.15 in GAAP EPS for its third quarter. Goldman Sachs set a $12 price target for the company in a November 2021 analyst note which stated that it is leading in its niche and that it has the potential to expand to the larger oncology, or cancer, market.
2. AbCellera Biologics Inc. (NASDAQ:ABCL)
SB Management’s holdings: $196 million
Percentage of SB Management’s Portfolio: 20.15%
Number of Hedge Fund Holders: 21
AbCellera Biologics Inc. (NASDAQ:ABCL) runs an artificial intelligence (AI) powered database of data from human immune systems. It utilizes this database to discover antibodies for drug development. It was founded in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc. (NASDAQ:ABCL) reported $5.51 million in revenue and a GAAP EPS of -$0.08 in its Q3 as it missed analyst estimates for both metrics. Piper Sandler set a $33 price target for the company in a November 2021 analyst note which claimed that AbCellera Biologics Inc. (NASDAQ:ABCL) can become the industry leader for antibody drug discoveries because of its technologies.
Mr. Son’s SB Management held 9.8 million AbCellera Biologics Inc. (NASDAQ:ABCL) shares during Q3 2021. These were worth $196 million and represented 20.15% of the firm’s portfolio. In the third quarter of 2021, out of the 867 hedge funds surveyed by Insider Monkey, 21 held a stake in the company.
AbCellera Biologics Inc. (NASDAQ:ABCL)’s largest shareholder is Julian Baker and Felix Baker’s Baker Bros. Advisors which holds 10.4 million shares worth $209 million.
1. Pacific Biosciences of California, Inc. (NASDAQ:PACB)
SB Management’s holdings: $208 million
Percentage of SB Management’s Portfolio: 21.35%
Number of Hedge Fund Holders: 27
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a gene sequencing system designer and manufacturer based in the United States. It was incorporated in 2000 and is headquartered in Menlo Park, California.
Mr. Son’s SB Management held 8.1 million Pacific Biosciences of California, Inc. (NASDAQ:PACB) shares by the end of the previous (Q3 2021) quarter, which were worth $208 million and represented 21.35% of the firm’s portfolio. Out of the 867 hedge funds surveyed by Insider Monkey during the same time period, 27 held a stake in the company.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) reported $34.8 million in revenue and $0.08 in GAAP EPS for its third quarter, beating analyst estimates on both counts. Canaccord set a $45 price target for the company in a September 2021 analyst note which highlighted that not only did Pacific Biosciences of California, Inc. (NASDAQ:PACB)’s machines provide highly accurate results, but that these were also heavily differentiated from its peers’ offerings.
Pacific Biosciences of California, Inc. (NASDAQ:PACB)’s largest shareholder is Catherine D. Wood’s ARK Investment Management who holds 22.7 million shares worth $580 million.
In its Q2 2021 investor letter, DEVON Equity Management mentioned California, Inc. (NASDAQ:PACB). It outlined that:
“As a final word on Sequencing – we established a position in Pacific Biosciences (PACB US) during the quarter. Pac Bio are the leader in Long Read Sequencing (Illumina are dominant in Short Read). The Long Read market is far less developed than short read, but our continued research into the genomic sequencing field increased our confidence in the commercial viability for Long Read Sequencing in the coming years. We will discuss the investment case for Pac Bio in more detail in a future letter.”
You can also take a peek at the 10 Stocks Cathie Wood Is Selling and 15 Best Financial Stocks to Buy Now.
